Revenue rose 49% but PBT loss doubled to NZ$5.8m

Annolyse's historical baseline classifies PBT growth, NPAT growth, EBITDA margin (-85.4%) and pre-lease free cash flow (-NZ$4.7m) at the lower edge of the recent range, so the result is the weakest of the supplied four-period window on those measures.

Operating cash outflow was essentially unchanged at NZ$4.6m, leaving cash at NZ$2.3m. The balance sheet contracted: total assets fell 26.5% to NZ$33.9m and equity fell 32.4% to NZ$19.0m, while gross borrowings declined only 6.2% to NZ$12.3m. Mix shifted decisively toward Honey, which grew to 69.7% of revenue from 51.8%, even as its segment loss tripled from NZ$0.3m to NZ$1.1m.

Revenue grew NZ$1.2m but the EBITDA loss deepened by NZ$1.3m, so each incremental dollar of sales lost money at the contribution level. The Honey segment doubled in revenue yet its segment loss roughly tripled, which means the mix shift toward the dominant segment is currently destroying margin rather than building scale economics.

Equity is eroding faster than losses are narrowing. Equity fell NZ$9.1m while the reported NPAT loss was NZ$5.8m, implying further capital absorption beyond the income-statement loss. With only NZ$2.3m of cash against a NZ$4.6m half-yearly operating burn and NZ$12.3m of borrowings, the runway question is now first-order; net-debt-to-EBITDA improved to 3.3x from 5.9x only because the denominator is a deeper loss in a smaller asset base.

Cash conversion fell but is not the lead issue. OCF/EBITDA dropped to 150.9% from 253.4%, which Annolyse's historical baseline still classifies as within the four-period normal range (mean 129.8%, range 58.5%–253.4%); the prior comparable was unusually strong. The deterioration is real but secondary to the question of whether the operating loss itself can be closed.

The supplied seasonality context shows HY22 represented only 29.2% of FY22 revenue and 14.2% of FY22 NPAT, meaning the business has historically been heavily second-half weighted. Annualising HY23 revenue gives NZ$7.2m, below FY22's NZ$8.3m, so meeting or beating last year's top line requires an H2 reacceleration that the release does not quantify.

Implied second-half NPAT in FY22 was a NZ$16.8m loss, dominated by impairment and restructuring per the FY22 commentary. The release does not indicate whether comparable below-EBITDA charges will recur, so an investor cannot infer whether FY23 NPAT will compress toward the H1 run-rate (~NZ$11.6m annualised) or be distorted again by one-offs.

Debtor days fell to 86.2 from 144.7 and inventory days fell to 791.2 from 1,064.8, which contained the cash burn at the prior-year level despite a deeper P&L loss. The working-capital movement of NZ$1.4m sits within Annolyse's historical baseline (mean NZ$0.3m, range -NZ$11.3m to NZ$14.7m), so this is normalisation rather than a one-off release.

The durability concern is structural rather than timing. Inventory at 791 days remains elevated in absolute terms and ties up NZ$15.6m of the NZ$33.9m balance sheet, so the trade-debtor improvement is small in context. Capex was negligible at NZ$0.015m (0.4% of revenue), which keeps reported FCF close to OCF but signals minimal reinvestment. Pre-lease FCF of -NZ$4.7m is below the four-period historical mean of -NZ$2.2m and at the bottom of the supplied range, reinforcing that the cash-flow profile has not stabilised.

This briefing cannot assess management's funding plan, gross margin by segment, or any post-balance-date capital raise, because none of those items are disclosed in the supplied release.